Lenograstim is a glycoprotein, with no hormonal effects of relevance for porphyrogenicity, and no effects on the mechanisms behind hepatic xenobiotic metabolism. However, side effects such as nausea and vomiting may be potentially porphyrinogenic through reduction in caloric intake.

Lenograstim is a recombinant glycoprotein.

Lenograstim is a granulocyte colony-stimulating factor used to treat or prevent neutropenia. It is also used to mobilise peripheral blood progenitor cells for collection and subsequent use in autologous or allogeneic peripheral blood stem cell transplantation. It is given by intravenous infusion or by subcutaneous injection. Common adverse reactions of lenograstim that can be confused with an acute porphyric attack are diarrhoea, abdominal pain, vomiting, skeletal pain, and muscle pain. Side effects such as nausea and vomiting may be potentially porphyrinogenic through reduction in caloric intake.

Lenograstim is considered to be metabolised to peptides and less than 1% of lenograstim is excreted in urine unchanged.